BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy

Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX) reported several near‑term and strategic advances: completed enrollment of 99 patients in its randomized, sham‑controlled Phase 2 BRTX‑100 trial, received a positive FDA Type B meeting aligning on Phase 3 and CMC, initiated Phase 3 enabling activities, and raised $5.0 million in a public offering to strengthen its balance sheet.

The company is also expanding a BioCosmeceutical commercial platform and advancing ThermoStem® IP while targeting a Phase 3 IND amendment in H2 2026 and Phase 2 topline results in early 2027.

Positive

• Enrollment complete: 99 patients in Phase 2 BRTX-100 trial
• Regulatory alignment: FDA Type B confirmation on Phase 3 design and CMC
• Balance sheet: $5.0 million public offering extended runway
• Program progression: Phase 3 enabling activities initiated

Negative

• Data timing: Phase 2 topline results not expected until early 2027
• Limited pre-BLA commercialization: Potential U.S. access restricted to select states prior to full approval

Key Figures

Recent public offering: $5 million Phase 2 enrollment: 99 patients Trial sites: 15 U.S. sites +3 more

6 metrics

Recent public offering $5 million Public offering referenced as strengthening balance sheet and runway

Phase 2 enrollment 99 patients Prospective, randomized, double-blind, sham-controlled Phase 2 trial of BRTX-100

Trial sites 15 U.S. sites Network for BRTX-100 Phase 2 chronic lumbar disc disease trial

Market size $28B Projected regenerative aesthetics market size by 2030

Phase 3 IND timing Second half 2026 Targeted submission of Phase 3 IND amendment for BRTX-100

Topline data timing Early 2027 Planned Phase 2 topline results timing after database lock and analysis

Market Reality Check

Price: $0.2083 Vol: Volume 2,520,860 is about...

low vol

$0.2083 Last Close

Volume Volume 2,520,860 is about 0.15x the 20-day average of 17,076,871, indicating muted trading interest ahead of this update. low

Technical Shares at 0.2083 are trading well below the 200-day MA of 1.35, and sit 90.08% below the 52-week high and 9.63% above the 52-week low.

Peers on Argus

BRTX slipped 2.57% while peers were mixed: APM down 2.83%, XTLB flat-to-up at 1....

1 Up 1 Down

BRTX slipped 2.57% while peers were mixed: APM down 2.83%, XTLB flat-to-up at 1.33%, BIVI up 6.2%, and PHGE up 14.86%. With gains in several peers and no common news theme, BRTX’s move appears stock-specific.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	IP/patent update	Positive	+37.0%	Australian patent allowance expanding ThermoStem® BADSC platform protection.
Feb 13	Financing close	Negative	-6.3%	Closing of $5.0M public offering with common shares and warrants.
Feb 11	Financing pricing	Negative	-40.5%	Pricing of $5.0M offering of 14,285,715 units at $0.35.
Feb 11	FDA meeting outcome	Positive	-35.4%	Positive FDA Type B meeting endorsing Phase 3 design and development plan.
Feb 10	Clinical milestone	Positive	-38.9%	Completion of enrollment of 99 patients in landmark BRTX-100 Phase 2 trial.

Pattern Detected

Recent history shows strong positive reaction to IP/patent news, while financing events have drawn selling, and key BRTX-100 clinical/regulatory milestones have sometimes been met with sharp declines, indicating occasional divergence between positive clinical news and price.

Recent Company History

Over the last month, BioRestorative has issued multiple material updates. On Feb 10, it completed enrollment of 99 patients in its BRTX-100 Phase 2 trial, followed by a positive FDA Type B meeting on Feb 11, clarifying a potential expedited BLA pathway. The stock sold off sharply on both. The company then priced and closed a $5.0M public offering around Feb 11–13, which also pressured shares. In contrast, a ThermoStem® IP allowance on Feb 24 drove a 37.01% gain. Today’s shareholder letter ties these strands together, emphasizing execution, regulatory alignment, and capital strategy.

Market Pulse Summary

This announcement consolidates BioRestorative’s recent milestones: completion of a 99-patient Phase ...

Analysis

This announcement consolidates BioRestorative’s recent milestones: completion of a 99-patient Phase 2 BRTX-100 trial, positive FDA Type B feedback on Phase 3 design and BLA strategy, and a $5 million offering that extends runway. It also emphasizes a biocosmeceutical revenue strategy in a projected $28B regenerative aesthetics market by 2030. Investors may track execution on the planned Phase 3 IND in the second half of 2026 and Phase 2 topline data expected in early 2027.

Key Terms

phase 2, phase 3, type b meeting, cmc, +1 more

5 terms

phase 2 medical

"fully powered Phase 2 trial of BRTX-100"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"Initiation of Phase 3 enabling activities"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

type b meeting regulatory

"positive FDA Type B meeting outcome"

A Type B meeting is a formal, scheduled discussion between a drug or medical-device developer and a health regulator to resolve key mid‑ or late‑stage development issues such as clinical trial plans, interpretation of results, or steps needed for approval. Like a mid‑project review with an inspector, the meeting’s outcome can meaningfully change the timeline, cost and risk for a candidate: a clear, positive outcome lowers uncertainty for investors, while requests for more data or changes can signal delays and extra expense.

cmc regulatory

"our Chemistry, Manufacturing, and Controls (CMC) framework was deemed appropriate"

Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

cGMP technical

"As a cGMP-compliant, ISO-7 cleanroom cell manufacturing organization"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

AI-generated analysis. Not financial advice.

Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum

MELVILLE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today issued the following letter to shareholders from Chief Executive Officer Lance Alstodt:

To our shareholders and stakeholders,

The first quarter of 2026 marks a pivotal period for BioRestorative Therapies. We have achieved significant milestones and have strong momentum across our clinical programs, regulatory pathways, commercial initiatives, and capital strategy. We believe the Company is well-positioned at a meaningful value inflection point, supported by:

• Completion of enrollment in our fully powered Phase 2 trial of BRTX-100
• Positive Type B regulatory outcome and alignment on the BLA pathway
• Initiation of Phase 3 enabling activities
• Strengthened capital position following a $5 million public offering
• Acceleration of our commercial BioCosmeceutical strategy
• Continued development of our ThermoStem^® metabolic platform
  
  

Independently, each of these milestones is value-creating. Collectively, they represent a convergence of clinical, regulatory, and commercial momentum.

BRTX-100: Execution Against a High Bar of Evidence

In February 2026, we completed enrollment of 99 patients across 15 U.S. sites in our prospective, randomized, double-blind, sham-controlled, single-disc Phase 2 trial of BRTX-100, our autologous hypoxically cultured mesenchymal stem cell therapy for chronic lumbar disc disease (cLDD). This study represents the largest and most rigorously designed FDA-authorized cell therapy trials conducted in cLDD. The sham-controlled design establishes a high evidentiary threshold — one consistent with registrational expectations and payer scrutiny in spine medicine. Rapid enrollment over the last 6 months across a broad network of investigators reflects both clinical demand and site engagement, reinforcing our view of the unmet need and potential commercial opportunity. It also reflects the positive momentum associated with a pristine safety profile and strong efficacy signal on blinded data. Topline results are expected following database lock and blinded statistical analysis.

FDA Type B Meeting: Regulatory Clarity and Risk Reduction

Amidst completion of enrollment, we held a Type B meeting with the U.S. Food and Drug Administration, during which we confirmed alignment on our proposed Phase 3 trial design, study endpoints and assumptions, dosing strategy, sample size, and powering assumptions. Importantly, no safety concerns were raised, and our Chemistry, Manufacturing, and Controls (CMC) framework was deemed appropriate for late-stage development. Regulatory alignment at this stage significantly reduces development pathway uncertainty and allows us to initiate Phase 3 enabling activities with increased confidence. We are targeting submission of a Phase 3 IND amendment in the second half of 2026. This regulatory progress is central to our capital allocation strategy and to our long-term value-creation plan, and these achievements provide meaningful clarity on a potential accelerated Biologics License Application (BLA).

BioCosmeceutical Commercial Platform: Near-Term Revenue Strategy

Our BioCosmeceutical platform represents a core pillar of our capital strategy and near-term revenue acceleration plan. We are expanding the distribution of products powered by our proprietary secretome-based biologics platform. The appointment of Crystal Romano as Head of Global Commercial Operations further strengthens our execution capabilities and positions us to accelerate commercialization across our cell-based portfolio. Crystal brings nearly two decades of executive leadership experience across the medical, aesthetics, and regenerative medicine sectors. This initiative is designed to generate non-dilutive revenue streams, support brand and manufacturing validation, and strategically offset development burn as we advance our clinical pipeline.

• BioCosmeceuticals sit at the intersection of skincare, aesthetics, and regenerative medicine, making them one of the fastest-growing segments in beauty and longevity, with the broader regenerative aesthetics market projected to exceed $28B by 2030. These products leverage biologically active ingredients that signal cell molecules that influence tissue repair pathways and are increasingly integrated into professional aesthetic procedures, medical-grade skincare, and at-home regenerative regimens. Clinics are rapidly adopting these solutions, with exosome treatments now used globally, signaling a clear shift: skincare is moving from cosmetic improvement to true biological performance
• BioRestorative is uniquely positioned to lead in this market by entering as a biotechnology company rather than a traditional beauty brand. As a cGMP-compliant, ISO-7 cleanroom cell manufacturing organization advancing therapeutic products under rigorous cell and tissue protocols, the Company brings fully integrated regenerative manufacturing and scientific infrastructure to a category largely driven by marketing-focused skincare brands. This foundation provides vertical control over cell sourcing, processing, quality systems, and scalable manufacturing, driving consistency, supply reliability, and long-term defensibility. BioRestorative’s therapeutic heritage also creates scientific credibility and regulatory discipline, critical differentiators in an emerging market, and enables the Company to translate regenerative science into differentiated, premium biocosmeceutical products.
• We are building a vertically integrated regenerative beauty platform engineered for scale, credibility, and premium monetization. Our three-channel strategy—global distribution partnerships, enterprise clinical adoption, and a high-margin direct-to-consumer engine—enables us to capture volume, validation, and recurring revenue simultaneously. Clinical integration drives authority, enterprise accounts provide predictable scale, and DTC extends in-office treatments into recurring at-home regimens, creating a powerful flywheel of demand and retention. The result is a scalable, defensible platform that combines biotech differentiation with beauty-level margins, positioning BioRestorative as a leader in next-generation regenerative skincare.
  
  

ThermoStem^®: Building Strategic Optionality with our Regenerative Medicine Platform for Obesity and Metabolic Disease

Our ThermoStem^® platform, focused on brown adipose-derived stem cell (BADSC) therapies for metabolic disorders, continues to expand its intellectual property estate. We recently received patent allowance in Australia covering the generation of non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates, strengthening global protection around our allogeneic, off-the-shelf metabolic platform. While BRTX-100 remains our primary value driver, ThermoStem^® represents strategic pipeline optionality in a large and rapidly evolving metabolic landscape. We continue to evaluate capital-efficient pathways to advance this program.

Capital Discipline and Balance Sheet Strategy

Following our recent $5 million public offering, we have strengthened our balance sheet and extended our operational runway. We are focused on maintaining optionality, advancing BRTX-100 through key data readouts, and preserving leverage ahead of potential partnership discussions. Throughout this period of rapid operational progress, we have remained disciplined in our capital strategy. This financing follows a previously completed registered direct offering that included participation from healthcare investors and members of our executive leadership team, reflecting confidence in our strategy, our science, and our execution capabilities.

Strategic Priorities for 2026

Advance BRTX-100 into Late-Stage Clinical Development

Our primary focus in 2026 is advancing BRTX-100 into late-stage development with regulatory clarity and operational readiness for BLA approval. This includes the initiation of Phase 3 enabling activities, the refinement of protocol elements consistent with prior FDA feedback, the confirmation of manufacturing readiness, and the submission of the Phase 3 IND amendment, targeted for the second half of 2026. These efforts are being sequenced deliberately to ensure alignment across regulatory, clinical, and manufacturing functions prior to trial initiation.

Deliver and Contextualize Phase 2 Data

We intend to report Phase 2 topline results in early 2027 in accordance with the pre-specified statistical analysis plan. Beyond reporting the data, our objective is to evaluate treatment effect, durability, and safety outcomes to inform Phase 3 design assumptions and long-term positioning in chronic lumbar disc disease. The results, together with regulatory feedback, will guide our registrational strategy and support informed strategic decision-making.

Advance BRTX-100 into Potential Strategic and Commercial Development

Outside the United States, commercial applications of cell-based biologics, such as stem cells, have advanced significantly over the past several years and have continued to grow in 2026. Recently, there has been a shift towards providing access to non-FDA-approved stem cell therapies for patients suffering from numerous musculoskeletal conditions, particularly back pain. Although not covered by insurance, states such as Utah, Wyoming, Texas, and Florida have instituted state laws that allow providers to offer therapies, such as BRTX-100, to patients. We intend to seek strategic and commercial partnerships within these states, which would allow us to potentially commercialize BRTX-100 prior to full BLA approval.

Develop the BioCosmeceutical Platform

Our BioCosmeceutical platform will continue to be developed with a focus on operational execution and margin discipline. We are working to expand practitioner adoption, optimize manufacturing throughput, and establish a more predictable commercial revenue base. This initiative is intended to complement our clinical development programs while leveraging our biologics manufacturing capabilities.

Advance ThermoStem^® with Capital Discipline

With respect to ThermoStem^®, our approach remains measured and financially disciplined. We will continue to seek to expand intellectual property protection and advance targeted preclinical and translational work to further characterize the platform and define its development pathway. We intend to pursue this business in a manner that preserves capital flexibility and prioritizes partnership avenues where appropriate.

Maintain Capital Allocation Discipline

We remain committed to disciplined capital deployment aligned with defined clinical and regulatory milestones. Our objective is to extend operational runway, manage dilution prudently, and preserve strategic flexibility. Financing, partnership, or other strategic alternatives will be evaluated in the context of long-term shareholder value and balance sheet stability. In 2026, our financial and operational decisions are guided by a clear prioritization of readiness for late-stage development of BRTX-100. Resources are being aligned to regulatory, manufacturing, and clinical preparation activities, while other initiatives will advance in a measured manner. Our objective is to maintain organizational focus as we approach the next stage of development.

We believe BioRestorative is transitioning from development-stage uncertainty toward late-stage regulatory clarity. Our focus remains on execution, data integrity, capital efficiency, and long-term shareholder value.

On behalf of our Board of Directors and the entire BioRestorative team, thank you for your continued confidence.

Sincerely,

Lance Alstodt
President, Chief Executive Officer and Chairman
BioRestorative Therapies, Inc.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Investors
CORE IR
investors@biorestorative.com

FAQ

What milestone did BioRestorative (BRTX) achieve in the BRTX-100 Phase 2 trial on March 4, 2026?

The company completed enrollment of 99 patients in the randomized, sham-controlled Phase 2 trial. According to the company, enrollment across 15 U.S. sites finished in February 2026, creating a fully powered dataset for blinded analysis and topline reporting.

What did the FDA Type B meeting mean for BioRestorative (BRTX) development plans?

The meeting confirmed alignment on Phase 3 design, endpoints, dosing, and CMC expectations. According to the company, no safety concerns were raised and the FDA agreed with proposed powering, reducing regulatory pathway uncertainty and enabling Phase 3 enabling activities.

When does BioRestorative (BRTX) expect to submit a Phase 3 IND amendment and report Phase 2 topline data?

The company targets a Phase 3 IND amendment in the second half of 2026 and Phase 2 topline results in early 2027. According to the company, these milestones will inform registrational strategy and Phase 3 design assumptions.

How does the $5.0 million public offering affect BioRestorative (BRTX) capital position and strategy?

The offering strengthened the company’s balance sheet and extended operational runway. According to the company, the financing supports advancing BRTX-100, preserves optionality for partnerships, and aims to manage dilution while funding near-term development and commercial initiatives.

What is BioRestorative’s plan for near-term revenue with its BioCosmeceutical platform (BRTX)?

The company is expanding distribution of secretome-based biologics across global partners, clinics, and DTC channels to generate non-dilutive revenue. According to the company, this strategy leverages cGMP manufacturing to validate supply, build brand credibility, and offset development burn.